Remdesivir: A beacon of hope from Ebola virus disease to <scp>COVID</scp>‐19

Nili, Ali; Farbod, Abolfazl; Neishabouri, Afarin; Mozafarihashjin, Mohammad; Tavakolpour, Soheil; Mahmoudi, Hamidreza

doi:10.1002/rmv.2133

Cited by 31 publications

(21 citation statements)

References 70 publications

(149 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The peptidomimetic GC-376 and the nucleoside analogue GS-441524, both able to inhibits FCoV replication in different manners, became available and were tested in vitro and in experimental infections (Kim et al, 2016;Murphy et al, 2018), or in cats naturally affected by FIP (Pedersen et al, 2018(Pedersen et al, , 2019. More specifically, GC-376 caused disease remission in 35% of the treated cats and it appeared more efficient towards certain clinical presentations of FIP (Pedersen et al, 2018 (Nili et al, 2020), and it would be interesting to consider how the bioavailability of the drug in the lung of COVID-19 patients may differ from that of the intestine or other tissues of cats with FIP.…”

Section: Tre Atmentmentioning

confidence: 99%

“…Anecdotal reports on therapeutic successes of this drug in cats with FIP are also published on online blogs, despite being an unlicensed drug as the other above mentioned. Clinical studies aimed to evaluate the effectiveness of Remdesivir treatment on COVID‐19 patients are currently ongoing (Nili et al., 2020), and it would be interesting to consider how the bioavailability of the drug in the lung of COVID‐19 patients may differ from that of the intestine or other tissues of cats with FIP.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID‐19): Are they similar?

Paltrinieri

Giordano

Stranieri

et al. 2020

Transbound Emerg Dis

View full text Add to dashboard Cite

Summary SARS‐CoV‐2 has radically changed our lives causing hundreds of thousands of victims worldwide and influencing our lifestyle and habits. Feline infectious peritonitis (FIP) is a disease of felids caused by the feline coronaviruses (FCoV). FIP has been considered irremediably deadly until the last few years. Being one of the numerous coronaviruses that are well known in veterinary medicine, information on FCoV could be of interest and might give suggestions on pathogenic aspects of SARS‐CoV‐2 that are still unclear. The authors of this paper describe the most important aspects of FIP and COVID‐19 and the similarities and differences between these important diseases. SARS‐CoV‐2 and FCoV are taxonomically distant viruses and recombination events with other coronaviruses have been reported for FCoV and have been suggested for SARS‐CoV‐2. SARS‐CoV‐2 and FCoV differ in terms of some pathogenic, clinical and pathological features. However, some of the pathogenic and immunopathogenic events that are well known in cats FIP seem to be present also in people with COVID‐19. Moreover, preventive measures currently recommended to prevent SARS‐CoV‐2 spreading have been shown to allow eradication of FIP in feline households. Finally, one of the most promising therapeutic compounds against FIP, GS‐441524, is the active form of Remdesivir, which is being used as one therapeutic option for COVID‐19.

show abstract

Section: Tre Atmentmentioning

confidence: 99%

Section: Treatmentmentioning

confidence: 99%

Feline infectious peritonitis (FIP) and coronavirus disease 19 (COVID‐19): Are they similar?

Paltrinieri

Giordano

Stranieri

et al. 2020

Transbound Emerg Dis

View full text Add to dashboard Cite

show abstract

“…Statistics and studies indicate that the Veklury (Remdesivir) drug was proposed to be used as an antiviral drug in managing and treating patients with COVID-19. The recommendations were based on earlier tests and clinical randomized trials developed in relation to drug use in treating and managing Ebola patients [ 26 , 27 ]. Tests on humans and animals demonstrated its safety and effectiveness in fighting the Coronavirus family viruses.…”

Section: Resultsmentioning

confidence: 99%

An Examination of COVID-19 Medications’ Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review

Al-Masaeed

Alghawanmeh

Al-Singlawi³

et al. 2021

Healthcare

View full text Add to dashboard Cite

Background: The review seeks to shed light on the administered and recommended COVID-19 treatment medications through an evaluation of their efficacy. Methods: Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review’s literature search was guided by the WHO solidarity clinical trials for COVID-19 scope and trial-assessment parameters. Results: The findings indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, minerals, and supplements has been linked to increased immunity and thus offering the body a fighting chance. Nevertheless, antibiotics do not correlate with improving patients’ wellbeing and are highly discouraged from the developed clinical trials. Conclusions: The review demonstrates the need for additional clinical trials with a randomized, extensive sample base and over a more extended period to examine the potential side effects of the medications administered. Critically, the findings underscore the need for vaccination as the only viable medication to limit the SARS-CoV-2 virus spread.

show abstract

“…Remdesivir is now the only drug approved by the US Food and Drug Administration with promising efficacy. 70 , 72 , 73 Of importance for dermatologists is the risk of skin rashes (8%) with this drug 72 ; however, remdesivir is not yet widely available in Iran.…”

Section: New Challengesmentioning

confidence: 99%